Back to search

Peptide record

TPDB92652

MTS Blood-Brain Barrier Cell-penetrating Peptides standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92652
MTS
Blood-Brain Barrier Cell-penetrating Peptides
Delivery and barrier-penetrating peptides
BBPpredict CellPPD CPPsite3.0 Peptipedia
standard
No
A 16-aa standard natural multi-activity (Blood-Brain Barrier and Cell-penetrating Peptides) peptide sequence curated from BBPpredict, CellPPD, CPPsite3.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
AAVALLPAVLLALLAP-NH2
Physicochemical Analysis
C74H130N16O17
RNDCEQGHIKMFSTWY
AL
1515.94
6.02
0
0
14
-0
-3.34
2.425
220.00
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
0
Residue Composition
number
6
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
6
L
0
K
0
M
0
F
2
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 6 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 6 K: 0 M: 0 F: 0 P: 2 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
16
C74H130N16O17
1515.94
6.02
-0
-3.34
2.425
Amidation
L
Amphipathic
Tetramer
Free
N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CS)C(=O)O
Evidence Records 1 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

Sk-Br-3, Jimt-1, A431, Jurkat-Cells

Assay & Model

Athymic BALB/c nude mice xenografted A431tumors
Athymic BALB/c nude mice xenografted A431tumors

Source & Reference

CPPsite3.0
CPPsite3
EP2928502B1

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Tetramer L Amphipathic
Protein derived
Anti-EGFR mAb matuzumab (Mat)
Lower internalization efficiency with values of 25% or less
Endocytosis
In vitro and in vivo
CCCCCCSGGGCCCCCCCC
Additional Detail Fields 1 fields
CCCCCCSGGGCCCCCCCC